Afshan N. Malik, Anabela Marisa Azul, Eugénia Carvalho, John G. Jones, Paulo Matafome, Paulo J. Oliveira
{"title":"Tackling overweight and obesity in the youth with the PAS GRAS project","authors":"Afshan N. Malik, Anabela Marisa Azul, Eugénia Carvalho, John G. Jones, Paulo Matafome, Paulo J. Oliveira","doi":"10.1038/s41591-025-03721-8","DOIUrl":null,"url":null,"abstract":"<p>It is a startling reality that today, over 245 million children aged 5–14, 249 million adolescents and young adults aged 15–24, and 2.1 billion adults are overweight or obese, with substantial increases for all age groups predicted for 2050<sup>1,2</sup>. The younger cohorts in particular are consigned to a lifetime of obesity-related comorbidities, whose treatment will consume an increasingly larger fraction of healthcare resources, with estimated costs reaching US$4.32 trillion by 2035<sup>3</sup>.</p><p>Youth obesity is particularly concerning because of the unique vulnerabilities of this age group and requires early intervention and decades of management<sup>5</sup>. Indicators of early onset metabolic complications, such as redox and energy imbalances, DNA methylation and transcriptional alterations, are already present in pre-pubertal children with obesity, resulting in greater adulthood metabolic risks. Many, if not most, of the determinants of lifetime obesity and metabolic sequelae are established during early stages of life. Investment in early childhood, from preconception to adolescence, can yield a 10:1 benefit:cost ratio in health and socioeconomic outcomes during later life<sup>5</sup>.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"19 1","pages":""},"PeriodicalIF":58.7000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41591-025-03721-8","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
It is a startling reality that today, over 245 million children aged 5–14, 249 million adolescents and young adults aged 15–24, and 2.1 billion adults are overweight or obese, with substantial increases for all age groups predicted for 20501,2. The younger cohorts in particular are consigned to a lifetime of obesity-related comorbidities, whose treatment will consume an increasingly larger fraction of healthcare resources, with estimated costs reaching US$4.32 trillion by 20353.
Youth obesity is particularly concerning because of the unique vulnerabilities of this age group and requires early intervention and decades of management5. Indicators of early onset metabolic complications, such as redox and energy imbalances, DNA methylation and transcriptional alterations, are already present in pre-pubertal children with obesity, resulting in greater adulthood metabolic risks. Many, if not most, of the determinants of lifetime obesity and metabolic sequelae are established during early stages of life. Investment in early childhood, from preconception to adolescence, can yield a 10:1 benefit:cost ratio in health and socioeconomic outcomes during later life5.
期刊介绍:
Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors.
Nature Medicine consider all types of clinical research, including:
-Case-reports and small case series
-Clinical trials, whether phase 1, 2, 3 or 4
-Observational studies
-Meta-analyses
-Biomarker studies
-Public and global health studies
Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.